Sign in
Taking peopleNo phase

Memory and thinking problems in people with primary aldosteronism

Follows people with primary aldosteronism to see how their memory and thinking change.

Key facts

Who runs it
Xinjiang Medical University
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
The Association Between Primary Aldosteronism and Cognitive Dysfunction
Status
Recruiting
People taking part
1,000 people, planned
Started
31 Dec 2025
Expected to end
Dec 2031
Type of study
Observational
Record updated
5 January 2026

Who can take part

The trial is looking for adults aged 40 or older with primary aldosteronism (PA), a hormone condition that raises blood pressure. It follows their memory and thinking for up to 5 years.

Age
40 years and older
Sex
All sexes
Disease stage
Primary aldosteronism confirmed by blood tests, with a positive screening test and a confirmatory test.
Biomarker or test result
Blood tests must confirm primary aldosteronism.
Main reasons for not taking part
  • Serious problems with sight, hearing or movement that prevent memory and thinking tests
  • Past major brain or nerve disease, such as stroke, Parkinson's disease, brain tumor or severe head injury
  • Past major mental illness, intellectual disability, or current use of antipsychotic medicines
  • High blood pressure caused by another condition than PA
  • Not willing to take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • 1. Aged ≥ 40 years
  • 2. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test)
  • 3. Ability to understand and cooperate with comprehensive neuropsychological assessment
  • 4. Voluntary participation and provision of written informed consent

Who cannot take part

  • 1. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing
  • 2. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury)
  • 3. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications
  • 4. Diagnosis of secondary hypertension other than PA
  • 5. Unwillingness to participate by the patient or their legal representative

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are:

Read full original descriptionShow less

1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it? 2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Association Between Primary Aldosteronism and Cognitive Dysfunction
Plain-language title
Memory and thinking problems in people with primary aldosteronismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07304674, who can take part
Record updated
5 January 2026